CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia

Kinase inhibitors that target Bcr-Abl are highly effective in the treatment of chronic myeloid leukemia (CML). However, these inhibitors are often invalidated due to the drug resistance. Therefore, the discovery and development of novel Bcr-Abl inhibitors is required to overwhelm the drug resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yinghui, Zhao, Na, Wang, Huan, Wu, Qiong, Han, Yunqi, Liu, Qichao, Wu, Mangang, Liu, Yuliang, Kong, Fansheng, Wang, He, Sun, Ying, Sun, Deguang, Jing, Lutao, Tang, Guojing, Hu, Yuandong, Xiao, Dengming, Luo, Hong, Han, Yongxin, Peng, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604209/
https://www.ncbi.nlm.nih.gov/pubmed/28928866
http://dx.doi.org/10.7150/jca.18731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604209/
https://www.ncbi.nlm.nih.gov/pubmed/28928866
http://dx.doi.org/10.7150/jca.18731

Ejemplares similares